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Glucagon-like peptide 1 receptor ago-
nists (GLP-1RAs) reduce cardiovascular
(CV) events among patients with type 2
diabetes and high CV risk. Because con-
sensus professional society recommen-
dations endorse metformin as the first-line
medication for type 2 diabetes, the CV
efficacy of GLP-1RAs has primarily been
studied with background metformin
therapy (1). However, the European So-
ciety of Cardiology now recommends
GLP-1RAs as a first-line type 2 diabetes
treatment for patients at high CV risk (2).
These discordant recommendations raise
the question of how background metfor-
min might influence the CV benefits of
GLP-1RAs. Using data from the LEADER
trial,we sought to answer this questionby
exploringpossibleheterogeneity in theCV
efficacy of liraglutide related to baseline
metformin treatment (3).
The Liraglutide Effect and Action in
Diabetes: Evaluation of Cardiovascu-
lar Outcome Results (LEADER) trial
(NCT01179048, ClinicalTrials.gov) has
been described elsewhere (3). Patients
with type 2 diabetes and high CV risk
underwent double-blind randomization
to daily liraglutide versus placebo in
addition to existing care.
Each patient contributed data from
randomization until censoring. The pri-
mary outcome was time from random-
ization to first occurrence of a composite
of CV death, myocardial infarction, or
stroke. Prespecified secondary outcomes
included an expanded composite (pri-
mary plus coronary revascularization or
hospitalization for unstable angina or
heart failure), the composite compo-
nents, and all-cause death. All outcomes
were centrally adjudicated.
Metformin treatment was identified at
the baseline trial visit and each visit
thereafter. Within each baseline metfor-
min treatment subgroup, effect estimates
for liraglutide versus placebo (hazard ratio
[HR], 95% CI) were derived using Cox
proportional hazards regression models;
multivariable adjustment for baseline de-
mographic and clinical factors was per-
formed. Inverse probability for treatment
weighting (IPTW) was used to account for
imbalances in covariates between base-
line metformin treatment subgroups (4).
For multivariable analyses with IPTW,
heterogeneity in the association between
baseline metformin treatment and the
effect of liraglutide was estimated using
stabilized, weighted Cox proportional
hazards models with randomization
group, baseline metformin treatment,
and the interaction of both as fixed
factors (5). A Pinteraction ,0.05 was held
to indicate a statistically significant differ-
ence in the treatment effect of liraglutide
across baseline metformin subgroups. In
order to explore the impact of post-
randomization changes in metformin use,
a sensitivity analysis repeated the main
IPTW analysis for the primary outcome
with censoring for initiation and discon-
tinuation of metformin during the study.
All data, methods, and study materials
are available on request.
Primary results of the LEADER trial
are presented elsewhere (3). Of 9,340
randomized participants, 7,144 (76%)
used metformin at baseline. There were
multipledifferences betweenbaselinemet-
formin subgroups; notably, metformin-
treated patients had shorter diabetes
duration, higher estimated glomerular
filtration rate (eGFR), lower heart failure
prevalence, and less insulinuse.All differ-
ences were attenuated by IPTW adjust-
ment. Irrespective of randomization
group, baseline metformin users had
lower risk of the primary outcome than
nonusers in multivariable analyses with
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IPTW (HRadjusted [95% CI] 0.72 [0.64;
0.81]).
In multivariable analyses with IPTW
(Fig. 1), liraglutide did not significantly
reduce incidenceof theprimaryoutcome
versus placebo among baseline metfor-
min users (HRadjusted [95% CI] 0.97 [0.85;
1.10]). Liraglutide did reduce incidence
of the primary outcome among baseline
metformin nonusers (HRadjusted [95% CI]
0.79 [0.64; 0.97]). Similar results were
seen for the expanded composite. The
P value for the interaction between
randomization group and baseline met-
formin treatment did not achieve statis-
tical significance for the primary outcome
(Pinteraction 5 0.10), the expanded com-
posite (Pinteraction 5 0.09), or other out-
comes (Fig. 1).
Among baseline metformin users,
658 (18.6%) receiving liraglutide and
585 (16.2%) receiving placebo discontin-
ued metformin during the trial. Among
baseline nonusers, 249 (22.1%) receiving
liraglutide and 299 (28.0%) receiving
placebo initiated metformin. Sensitiv-
ity analysis results were similar to the
main analysis for the primary outcome
within baselinemetforminuser (HRadjusted
[95% CI] 0.94 [0.82; 1.08]) and nonuser
(HRadjusted [95% CI] 0.71 [0.55; 0.90])
subgroups. The interaction between
randomization group and baseline met-
formin treatment did achieve statistical
significance in the sensitivity analysis
(Pinteraction 5 0.046).
Whether background metformin treat-
mentmodifies the CV effects of GLP-1RAs
is a foundational question underlying
debates as to the optimal first-line
type 2 diabetes treatment for patients
with high CV risk. Although the effects of
liraglutide appeared greater in the sub-
group without baseline metformin treat-
ment, our main analyses did not show
statistically significant interactions be-
tween liraglutide treatment and metfor-
min use. These findings may indicate that
the CV benefits of liraglutide do not rely
upon prior metformin treatment. As such,
discussions regardingfirst-line treatment
for type 2 diabetes in individuals with
high CV risk should continue to focus on
the absolute effectiveness of the agents
in question, with appropriate consider-
ation of costs to patients and society.
We conducted a sensitivity analysis
exploring how postrandomization changes
in metformin treatment impacted the in-
teraction between randomization group
and baseline metformin use. While CV
effect estimates for liraglutide within
the baseline metformin subgroups were
similar to themainanalysis, the interaction
did achieve statistical significance in the
sensitivity analysis. Analyzing non-
randomized exposures is challenging, and
postrandomization changes in metformin
use likely occurred for cause; interpreting
this sensitivity analysis thus requires
caution.
The present analyses add to existing
evidence regarding the potential influ-
ence of metformin on the CV efficacy of
newer diabetes agents. Previously, one
n n P
Figure 1—Effects of liraglutide (vs. placebo) onCVoutcomes amongpatientswith andwithout baselinemetformin use, adjusted for baseline covariates
with inverse probability weighting. Shaded squares5metformin use at baseline; empty diamonds5 nometformin use at baseline. HRs derived using
a Cox proportional hazards regression model with randomization group, baseline metformin exposure, and the interaction of both as factors, and
diabetes duration, eGFR, and age at baseline as additional covariates, adjusted for baseline covariates: age, sex, region, diabetes duration, HbA1c,
antihyperglycemic medication, eGFR, smoking, prior myocardial infarction, heart rhythm disorders, heart failure, left ventricular systolic dysfunction,
left ventricular diastolic dysfunction, prior ischemic stroke, prior transient ischemic attack, prior hemorrhagic stroke, prior percutaneous coronary
intervention, prior coronary bypass surgery, intracranial artery stenosis, carotid artery stenosis, peripheral arterial disease, and $50% stenosis of
coronary, carotid, or other arteries. MI, myocardial infarction; n, number of patients with event; PYO, patient-years of observation; %, proportion of
patients in subgroup with event.
GLP-1RA trial reported an unadjusted
secondary analysis showing that the CV
effects of albiglutide did not differ sig-
nificantly across baseline metformin
subgroups (6). A secondary analysis in-
corporating adjustment for baseline dif-
ferences found that empagliflozin was
associated with CV benefits irrespective
of baseline metformin use (7). A trial-
level meta-analysis without adjustment
for baseline differences suggested pos-
sible variability in CV outcomes with
dipeptidyl peptidase 4 inhibitors favor-
ing baseline metformin users (8). Be-
cause potentially confounding factors
like eGFR and heart failure prevalence
may be independently associated with
both baseline metformin use and CV
outcomes, adjustment for propensity to
receive metformin (as well as baseline
differences) is critical and was a partic-
ular strength of our approach.
Importantly, the LEADER trial was not
explicitly designed to evaluate the pres-
ent research question. An appropriately
powered randomized trial would be re-
quired to definitively ascertain hetero-
geneity in the CV efficacy of liraglutide.
In conclusion, we identified no clear
evidence for heterogeneity in the CV
efficacy of liraglutide based on back-
ground metformin use.
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